Oculis Holding AG OCS 深 滬

美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级

今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元

今天 11:46

HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $44 to $47.

今天 00:48

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Holding AG will present updates on its late-stage pipeline and key unmet medical needs in ophthalmology at the ARVO 2026 Annual Meeting. Highlights include findings from the DME AWARE Delphi Study emphasizing the need for non-invasive therapies for diabetic macular edema (DME), post-hoc analysis of Privosegtor's impact on retinal ganglion cell loss in optic neuritis, and a corporate update on upcoming milestones. The company is advancing O...

05-01 08:00

美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价

今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元

04-21 11:25

Oculis Completes Final Patient Visits In Both Phase 3 DIAMOND Trials For OCS-01 Diabetic Macular Edema Eye Drop Treatment

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026A non-invasive topical treatment for diabetic macular edema (DME) has the potential

04-20 17:31

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

04-20 08:00

Oculis to Participate in Upcoming Investor Conferences

04-07 08:00

Oculis Receives European Medicines Agency PRIME Designation For Privosegtor In Optic Neuritis, Accelerating PIONEER Registrational Program Across Three Global Trials

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual

03-31 16:10

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis Holding AG announced that its neuroprotective candidate, Privosegtor, has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of optic neuritis (ON), a rare, sight-threatening condition. This follows a Breakthrough Therapy designation from the U.S. FDA in January 2026, highlighting the potential of Privosegtor as the first neuroprotective therapy for ON. The designation is supported ...

03-31 08:00

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding AG announced the presentation of Phase 2 ACUITY trial results for Privosegtor at the NANOS 2026 Annual Meeting, showcasing significant improvements in low-contrast visual acuity and neuroprotective effects in patients with optic neuritis (ON). Privosegtor, a novel peptoid small molecule, has the potential to become the first neuroprotective therapy for ON, with Breakthrough Therapy designation from the FDA. The trial results highli...

03-16 09:00